Transplant News and Research

RSS

$Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma$

Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma.

29 Apr 2025

Routine molecular monitoring doubles survival in high-risk AML subtypes

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukemia (AML) by helping doctors identify if they might relapse up to three months earlier.

29 Apr 2025

HOPE technique shows promise for long-term donor lung preservation

A study on donor lungs preserved outside the body before transplantation demonstrated that the hypothermic oxygenated machine perfusion (HOPE) technique is a safe and effective lung preservation method, even with total out-of-body times approaching 20 hours.

27 Apr 2025

Heart transplant volume rises with adoption of DCD techniques

Researchers at the Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) marked the 10-year anniversary of modern heart donation after circulatory death (DCD), a technique that has significantly increased transplant volumes around the world.

27 Apr 2025

Machine perfusion extends long-distance heart transplant possibilities

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

27 Apr 2025

Malaria infection linked to childhood cancer risk

New data published in The Journal of Immunology uncovered the role of Plasmodium falciparum infection (malaria) in the development of Burkitt lymphoma (BL), the most common childhood cancer in equatorial Africa and New Guinea.

25 Apr 2025

Long COVID poses lasting health risks for young people

Long COVID can result in increased risk for a variety of serious health problems for young people, including those affecting the kidney, gut, and cardiovascular system, according to a group of new studies led by investigators at the Perelman School of Medicine at the University of Pennsylvania.

21 Apr 2025

Hydroxyurea shows long-term benefits for children with sickle cell disease

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with sickle cell disease (SCD), according to new research published in Blood Advances.

17 Apr 2025

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

17 Apr 2025

Humanized liver organoids double survival rate in rodent models

One reason why our livers excel at clearing waste from our blood system is that the organ functions according to three key "zones" that perform specific major tasks.

16 Apr 2025

Stem cell therapy shows promise for treating advanced Parkinson's disease

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical trial reported in Nature.

16 Apr 2025

Multi-omics analysis uncovers molecular drivers of non-viral liver cancer development

Researchers discover that inflammation and aging contribute to non-viral liver cancer development. Green tea's role in reversing some of the pathway dysregulation that may contribute to the cancer development and other therapies explored.

15 Apr 2025

Refining the diagnosis of large granular lymphocytic leukemias and their mimics

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL) are the most prominent.

10 Apr 2025

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

8 Apr 2025

Human dental stem cells can be transformed into excitable neuronal cells, study shows

The cells with electrophysiological activity obtained at the University of the Basque Country (UPV/EHU) are opening up new avenues for the study of neurodegenerative diseases and the development of future autologous transplants.

7 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Genetic research offers hope for children with rare intestinal disorders

Further genetic testing would show that Sophie has one of a group of rare conditions called CODE (congenital diarrhea and enteropathies) that disrupts the function of cells in the intestine, causing diarrhea and preventing infants from absorbing the nutrients they need to grow and thrive.

3 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Study finds no benefit of early IABP use in cardiogenic shock patients

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart failure did not improve 60-day survival or enable more patients to successfully transition to long-term treatment, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC

31 Mar 2025